Premium
Mannose‐6‐Phosphate Receptor: A Target for Theranostics of Prostate Cancer
Author(s) -
Vaillant Ophélie,
Cheikh Khaled El,
Warther David,
Brevet David,
Maynadier Marie,
Bouffard Elise,
Salgues Frédéric,
Jeanjean Audrey,
Puche Pierre,
Mazerolles Catherine,
Maillard Philippe,
Mongin Olivier,
BlanchardDesce Mireille,
Raehm Laurence,
Rébillard Xavier,
Durand JeanOlivier,
GaryBobo Magali,
Morère Alain,
Garcia Marcel
Publication year - 2015
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201500286
Subject(s) - mannose , prostate cancer , nanomedicine , mannose 6 phosphate , cancer research , in vivo , lectin , chemistry , in vitro , cancer , mannose receptor , cancer cell , biochemistry , nanotechnology , receptor , nanoparticle , medicine , materials science , biology , growth factor , microbiology and biotechnology , macrophage
Abstract The development of personalized and non‐invasive cancer therapies based on new targets combined with nanodevices is a major challenge in nanomedicine. In this work, the over‐expression of a membrane lectin, the cation‐independent mannose 6‐phosphate receptor (M6PR), was specifically demonstrated in prostate cancer cell lines and tissues. To efficiently target this lectin a mannose‐6‐phosphate analogue was synthesized in six steps and grafted onto the surface of functionalized mesoporous silica nanoparticles (MSNs). These MSNs were used for in vitro and ex vivo photodynamic therapy to treat prostate cancer cell lines and primary cell cultures prepared from patient biopsies. The results demonstrated the efficiency of M6PR targeting for prostate cancer theranostic.